These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2540650)

  • 1. Differential effects of non-specific beta-blockade and calcium antagonism on blood-clotting mechanisms.
    Gleerup G; Winther K
    Am J Med; 1989 Apr; 86(4A):127-9. PubMed ID: 2540650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased fibrinolytic activity and increased platelet function in hypertension. Possible influence of calcium antagonism.
    Gleerup G; Winther K
    Am J Hypertens; 1991 Feb; 4(2 Pt 2):168S-171S. PubMed ID: 1827012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does calcium channel blockade and beta-adrenergic blockade affect platelet function and fibrinolysis to a varying degree?
    Gleerup G; Mehlsen J; Winther K
    J Cardiovasc Pharmacol; 1995 Jan; 25(1):87-9. PubMed ID: 7723358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of isradipine sustained release on platelet function and fibrinolysis in essential hypertensives with or without other risk factors.
    Ranieri G; Filitti V; Andriani A; Bonfantino MV; Lamontanara G; Cavallo A; Milani M; De Cesaris R
    Cardiovasc Drugs Ther; 1996 May; 10(2):119-23. PubMed ID: 8842503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet function and fibrinolytic activity in hypertension: differential effects of calcium antagonists and beta-adrenergic receptor blockers.
    Winther K; Gleerup G; Hedner T
    J Cardiovasc Pharmacol; 1991; 18 Suppl 9():S41-4. PubMed ID: 1725542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced risk of thromboembolic disease in hypertension from platelet hyperfunction and decreased fibrinolytic activity: has antihypertensive therapy any influence?
    Winther K; Gleerup G; Hedner T
    J Cardiovasc Pharmacol; 1992; 19 Suppl 3():S21-4. PubMed ID: 1376829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isradipine improves platelet function in hypertensives.
    Sinzinger H; Virgolini I; Rauscha F; Fitscha P; O'Grady J
    Eur J Clin Pharmacol; 1992; 42(1):43-6. PubMed ID: 1531796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of isradipine on platelet function in hypertension at rest and during exercise.
    Fitscha P; Virgolini I; Rauscha F; Sinzinger H
    Am J Hypertens; 1991 Feb; 4(2 Pt 2):178S-180S. PubMed ID: 1827015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pro-haemorrhagic effects of calcium antagonists: a comparison of isradipine and atenolol on ex vivo platelet function in hypertensive subjects.
    Smith A; McPherson J; Taylor M; Mason A; Carney S; Gillies A
    J Hum Hypertens; 1997 Dec; 11(12):783-8. PubMed ID: 9468004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved blood pressure control with isradipine in hypertensive patients treated with pindolol.
    Frithz G; Aström B; Dahlöf B; Hansson L; Tollin C; Himanen P; Sundstedt CD
    Am J Med; 1989 Apr; 86(4A):115-8. PubMed ID: 2523645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet-activating effect of low-density lipoprotein and its reversal by isradipine.
    Fetkovská N; Fedelesová V; Kozlovský M; Dzúrik R
    Am J Hypertens; 1991 Feb; 4(2 Pt 2):175S-177S. PubMed ID: 1827014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet aggregation and metabolic control are not affected by calcium antagonist treatment in type II diabetes mellitus.
    Klauser R; Speiser P; Gisinger C; Schernthaner G; Prager R
    J Cardiovasc Pharmacol; 1990; 15 Suppl 1():S93-6. PubMed ID: 1695314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does antihypertensive therapy affect the natural protection against thrombosis?
    Gleerup G; Hedner T; Hjørting Hansen E; Winther K
    J Cardiovasc Pharmacol; 1991; 18 Suppl 3():S34-6. PubMed ID: 1720483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the calcium antagonist isradipine on 24-hour ambulatory blood pressure, platelet aggregation, and neutrophil oxygen free radicals in hypertension.
    Ding YA; Han CL; Chou TC; Lai WY; Shiao MF
    J Cardiovasc Pharmacol; 1992; 19 Suppl 3():S32-7. PubMed ID: 1376832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter evaluation of the safety and efficacy of isradipine in hypertension. The Italian-Belgian Isradipine Study Group.
    Am J Med; 1989 Apr; 86(4A):94-7. PubMed ID: 2523664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive effects of isradipine and captopril as monotherapy or in combination.
    Fitscha P; Meisner W; Hitzenberger G
    Am J Hypertens; 1991 Feb; 4(2 Pt 2):151S-153S. PubMed ID: 1827007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter evaluation of the safety and efficacy of isradipine and atenolol in the treatment of hypertension. Isradipine in Hypertension Study Group.
    Am J Med; 1989 Apr; 86(4A):119-23. PubMed ID: 2523646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additive effect of isradipine in combination with captopril in hypertensive patients.
    Eggertsen R; Svensson A; Dahlöf B; Hansson L
    Am J Med; 1989 Apr; 86(4A):124-6. PubMed ID: 2523647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotonin and platelet activation during treatment with isradipine.
    Fetkovska N; Sebekova K; Fedelesova V; Dzurik R
    J Cardiovasc Pharmacol; 1991; 18 Suppl 3():S31-3. PubMed ID: 1720482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal and hemodynamic effects of isradipine in essential hypertension.
    Persson B; Andersson OK; Wysocki M; Hedner T; Aurell M
    Am J Med; 1989 Apr; 86(4A):60-4. PubMed ID: 2523657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.